A Phase 3 interventional study of ZD4054 and Placebo in Prostate Cancer, sponsored by AstraZeneca. Completed at 199 sites in 31 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 10th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2007, is one of 17 in phase 3, and was the 15th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 18 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Australia, Germany and 4 more countries
Ages 18–99 · Men only
AstraZeneca · Sites in United States, Australia, Korea, Republic of
Ages 18–100 · Men only
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Brazil, China and 7 more countries
Ages 18–130 · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 17 · Phase 4 4
First in 1994; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 896 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 110 across the 60 interventional studies, 310 across the 29 observational. Of the 58 that completed or were terminated, 11 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Prostatic Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06120491Phase 3AstraZenecaSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | 2027-09-30 |
| NCT06267729AstraZenecaStudy of AZD0754 in Participants With Metastatic Prostate Cancer | 2026-11-24 |
| NCT06402331Fusion Pharmaceuticals Inc.FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2026-12-23 |
| NCT06380738AstraZenecaReal-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) | 2027-02-14 |
| NCT07560215AstraZenecaPROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who answer TRUE to the following criteria may be eligible to participate in this trial.
Exclusion Criteria:
Patients who answer TRUE to the following may NOT eligible to participate in this trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZD4054 10 mg oral tablet once daily
Drug: ZD4054
Matching Placebo, oral tablets once daily
Drug: Placebo
ZD4054 10 mg oral tablet once daily
Also known as: Zibotentan
Matching placebo oral tablet once daily
Overall Survival
Median time (in months) from randomisation until death using the Kaplan-Meier method
Time frame: From date of randomization until date of death, assessed up to 32 months
Progression Free Survival
Median time (in months) from randomisation until clinical progression of disease, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline, using the Kaplan-Meier method
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 31 months
Time to Use of Opiates
Median time (in months) from randomisation until use of opiates for disease-related symptoms for a duration ≥1 week using the Kaplan-Meier method
Time frame: From date of randomization until use of opiates for disease-related symptoms for a duration ≥1 week, assessed up to 31 months
Incidence of Skeletal Related Events
Median time (in months) from randomisation until occurrence of a skeletal related event, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression, using the Kaplan-Meier method.
Time frame: From date of randomization until occurrence of a skeletal related event, assessed up to 31 months
Bone Metastases Formation
Median time (in months) from randomisation to appearance of ≥4 new bone lesions using the Kaplan-Meier method
Time frame: Patients were assessed every 12 weeks
Health Related Quality of Life
Median time (in months) from randomisation until deterioration of Health related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.
Time frame: Patients were assessed at every visit
Time to Prostate-specific Antigen (PSA) Progression
Median time (in months) from randomisation to first PSA value \>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.
Time frame: Patients were assessed every 12 weeks
Time to Pain Progression
Median time (in months) from randomisation to first assessment of an increased pain event, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.
Time frame: Patients were assessed every 12 weeks
Time to Initiation of Chemotherapy
Median time (in months) from randomisation to first administration of any chemotherapy using the Kaplan-Meier method
Time frame: Patients were assessed every 12 weeks
Pharmacokinetic Characteristics of ZD4054
Time frame: PK samples were performed at randomisation, Week 4, Week 8 and Week 12
896 patients with hormone-resistant prostate cancer patients and bone metastasis were recruited between 20th November 2007 and 13th February 2009.
| Milestone | ZD4054 | Placebo |
|---|---|---|
| Started | 299 | 295 |
| Patients who received treatment | 298 | 295 |
| Completed | 73 | 70 |
| Not completed | 226 | 225 |
| Withdrew: Lost to follow-up | 3 | 6 |
| Withdrew: Withdrawal by subject | 29 | 37 |
| Withdrew: Adverse event | 71 | 39 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Reason not otherwise captured, eg; death | 119 | 140 |
| Withdrew: Randomised but no treatment received | 1 | 0 |
Median time (in months) from randomisation until death using the Kaplan-Meier method
| months | ZD4054 | Placebo |
|---|---|---|
| Overall Survival | 24.5 (0.5 to 31.2) | 22.5 (0.5 to 29.8) |
Median time (in months) from randomisation until clinical progression of disease, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline, using the Kaplan-Meier method
| Months | ZD4054 | Placebo |
|---|---|---|
| Progression Free Survival | 6.2 (2.8 to 13.8) | 6.5 (2.8 to 13.2) |
Median time (in months) from randomisation until use of opiates for disease-related symptoms for a duration ≥1 week using the Kaplan-Meier method
| Months | ZD4054 | Placebo |
|---|---|---|
| Time to Use of Opiates | 16.7 (7.3 to 27.0) | 14.8 (7.9 to 25.8) |
Median time (in months) from randomisation until occurrence of a skeletal related event, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression, using the Kaplan-Meier method.
| Months | ZD4054 | Placebo |
|---|---|---|
| Incidence of Skeletal Related Events | 18.4 (9.6 to 30.6) | 17.1 (9.3 to 25.8) |
Median time (in months) from randomisation to appearance of ≥4 new bone lesions using the Kaplan-Meier method
| Months | ZD4054 | Placebo |
|---|---|---|
| Bone Metastases Formation | 15.1 (7.2 to 25.5) | 11.9 (7.0 to 22.5) |
Median time (in months) from randomisation until deterioration of Health related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.
| Months | ZD4054 | Placebo |
|---|---|---|
| Health Related Quality of Life | 5.5 (2.8 to 9.1) | 5.5 (2.8 to 9.1) |
Median time (in months) from randomisation to first PSA value \>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.
| Months | ZD4054 | Placebo |
|---|---|---|
| Time to Prostate-specific Antigen (PSA) Progression | 5.6 (2.9 to 11.1) | 5.6 (2.8 to 11.4) |
Median time (in months) from randomisation to first assessment of an increased pain event, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.
| Months | ZD4054 | Placebo |
|---|---|---|
| Time to Pain Progression | 9.0 (3.3 to 19.4) | 8.4 (3.4 to 19.1) |
Median time (in months) from randomisation to first administration of any chemotherapy using the Kaplan-Meier method
| Months | ZD4054 | Placebo |
|---|---|---|
| Time to Initiation of Chemotherapy | 11.4 (5.8 to 18.5) | 10.6 (6.0 to 18.2) |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZD4054 | — | 98/298 (32.9%) | 257/298 (86.2%) |
| Placebo | — | 105/295 (35.6%) | 221/295 (74.9%) |
| Event | ZD4054 | Placebo |
|---|---|---|
| DeathGeneral disorders | 2/298 | 7/295 |
| AnaemiaBlood and lymphatic system disorders | 6/298 | 1/295 |
| Cardiac FailureCardiac disorders | 6/298 | 0/295 |
| PneumoniaInfections and infestations | 6/298 | 1/295 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 5/298 | 2/295 |
| Renal Failure AcuteRenal and urinary disorders | 1/298 | 4/295 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 4/298 | 0/295 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/298 | 3/295 |
| NeutropeniaBlood and lymphatic system disorders | 2/298 | 3/295 |
| SepsisInfections and infestations | 3/298 | 3/295 |
| Event | ZD4054 | Placebo |
|---|---|---|
| Oedema PeripheralGeneral disorders | 132/298 | 56/295 |
| HeadacheNervous system disorders | 92/298 | 37/295 |
| NauseaGastrointestinal disorders | 62/298 | 44/295 |
| ConstipationGastrointestinal disorders | 61/298 | 51/295 |
| FatigueGeneral disorders | 58/298 | 52/295 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 48/298 | 9/295 |
| DiarrhoeaGastrointestinal disorders | 28/298 | 46/295 |
| AnaemiaBlood and lymphatic system disorders | 46/298 | 33/295 |
| Decreased AppetiteMetabolism and nutrition disorders | 44/298 | 37/295 |
| Back PainMusculoskeletal and connective tissue disorders | 35/298 | 37/295 |
| Age, Continuous(Years) | ZD4054 | Placebo | Total |
|---|---|---|---|
| Overall | 70.2 ± 7.8 | 70.9 ± 8.6 | 70.5 ± 8.2 |
| Sex: Female, Male(Participants) | ZD4054 | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 299 | 295 | 594 |
Showing the first 100 of 199 sites across 31 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2007, a primary completion of Jul 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054